South Africa's BEAT Tuberculosis study improves drug-resistant TB treatment

Findings from South Africa's BEAT Tuberculosis study, published in the New England Journal of Medicine, show a new six-month regimen cures 90 percent of drug-resistant TB cases.

The clinical study began in Gqeberha in the Eastern Cape to test the safety and effectiveness of a shortened treatment for drug-resistant tuberculosis.

Dr Francesca Conradie of the Clinical Health Research Unit at Wits University described the change. She said previous regimens lasted 18 months with daily injections for the first six months, cured only half the patients, and caused side effects such as hearing loss, nausea and vomiting.

The new approach lasts six months and achieves a 90 percent cure rate, according to the study results released this week.

관련 기사

South Africa has started rolling out the twice-yearly HIV prevention injection lenacapavir, though success depends on managing interactions with common tuberculosis medicines.

AI에 의해 보고됨

A new combination pill containing bictegravir and lenacapavir shows promise for people with HIV who require complex regimens. The phase three ARTISTRY 1 study found it performed as well as existing multi-pill options. Experts note its impact in South Africa will likely remain limited.

An experimental mRNA vaccine has demonstrated effectiveness against three strains of Ebola virus in rodent tests. The vaccine targets Zaire, Sudan and Bundibugyo viruses. Researchers developed it amid an ongoing outbreak of Bundibugyo virus in Africa.

AI에 의해 보고됨

A new treatment called Daraxonrasib has shown strong results against advanced pancreatic cancer in a recent clinical trial. The drug targets a genetic mutation long considered impossible to treat effectively.

이 웹사이트는 쿠키를 사용합니다

사이트를 개선하기 위해 분석을 위한 쿠키를 사용합니다. 자세한 내용은 개인정보 보호 정책을 읽으세요.
거부